Determination of abacavir in human plasma by high-performance liquid chromatography with ultraviolet detection and the analytical error function

Biomedical Chromatography

Volumn 18, Issue 10, 2004, Pages 862-865

  Ferrer, Salut M ^a   Modamio, Pilar ^a   Lastra, Cecilia F ^a   Mariño, Eduardo L ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Abacavir; Analytical error function; HPLC; Human plasma

Indexed keywords

COLUMN CHROMATOGRAPHY; DISEASES; EXTRACTION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; PLASMA (HUMAN);

ABACAVIR; ANALYTICAL ERROR FUNCTION; ANALYTICAL ERRORS; ERROR-FUNCTION; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HPLC; HUMAN PLASMAS; SIMPLE++; ULTRA VIOLET DETECTION; ULTRAVIOLET DETECTION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ABACAVIR; ACETIC ACID ETHYL ESTER; ACETONITRILE; ETHER; RNA DIRECTED DNA POLYMERASE INHIBITOR; WATER;

ACCURACY; ANALYTICAL ERROR; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; FLOW RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR SYSTEM; LIQUID LIQUID EXTRACTION; PATIENT MONITORING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TIME; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 11844304969     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.406     Document Type: Article

References (23)

1. Aymard GM, Legrand M, Trichereau N and Diquet B. Determination of twelve antiretrovital agents in human plasma sample using reversed-phase high performance liquid chromatography. Journal of Chromatography B 2000; 744: 227-240.
2. Causon R. Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. Journal of Chromatography B 1997; 689: 175-180.
3. Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT and Stein DS. Abacavir (1592U89): absolute bioavailability and effect on food. Pharmacotherapy 1999; 19: 932-942.
4. Clay PG. The abacavir hypersensitivity reaction: a review. Clinical Therapy 2002; 10: 1502-1514.
5. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, Johnson M, Gazzard B, Stone C, Athisegaran R, Moore S and CNA30017 Study Team. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1517-1526.
6. Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, Tisdale M, Parry NR, Reardon JE, Dornsife RE, Averett DR and Krenitsky TA. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrobial Agents and Chemotherapy 1997; 41: 1082-1093.
7. Fung EN, Cai Z, Burnette TC and Sinhababa AK. Simultaneous determination of Ziagen and its phosphorilated metabolites by ion-pairing high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 2001; 754: 285-295.
8. Hedaya MA and Sawchuk RJ. A sensitive liquid-chromatographic method for determination of 3′-azido-3′-deoxythymidine (AZT) in plasma and urine. Clinical Chemistry 1988; 34: 1565-1568.
9. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G and Steel H. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clinical Therapy 2001; 23: 1603-1614.
10. Jansat JM, Lastra CF and Mariñio EL. Comparative study of different weighting methods in non-linear regression analysis: implications in the parametrization of carebastatine after intravenous administration in healthy voluntees. International Journal of Clinical and Pharmacological Therapy 1998; 36: 340-344.
11. Karnes HT, Shin G and Shah V. Validation of bioanalytical methods. Pharmaceutical Research 1991; 8: 421-426.
12. Modamio P, Lastra CF and Mariño EL. Determination of analytical error function for β-blockers as a possible weighting method for the estimation of the regression parameters. Journal of Pharmaceutical and Biomedical Analysis 1996; 14: 401-408.
13. Moyer TP, Temesgen Z, Enger R, Estes L, Charlson J, Oliver L and Wright A. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clinical Chemistry 1999; 45: 1465-1476.
14. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E, Battegay M, Ledergerber B, Gunthard H, Howe C, Weber R, Perrin L and Swiss HIV Cohort Study. A randomised trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. Journal of Infectious Diseases 2002; 185: 1251-1260.
15. Peyriere H, Guillemin V, Lotthe A, Baillat V, Fabre J, Favier C, Atoui N, Hansel S, Hillaire-Buys D and Reynes J. Reasons for early abacavir discontinuation in HIV-infected patients. Annals of Pharmacotherapy 2003; 37: 1392-1397.
16. Ravitch JR and Moseley CG. High performance liquid chromatographic assay for abacavir and its two major metabolites in human urine and cerebrospinal fluid. Journal of Chromatography B 2001; 762: 165-173.
17. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA and Spector S. Analytical methods validation: bsioavailability, bioequivalence and pharmacokinetic studies. Pharmaceutical Research 1992; 9: 588-592.
18. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT and Yacobi A. Bioanalytical method validation: a revisit with a decade of progress. Pharmaceutical Research 2000; 17: 1551-1557.
19. Simon VA, Thiam MD and Lipford LC. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. Journal of Chromatography A 2001; 913: 447-453.
20. Unadkat JD, Crosby SS, Wang JP and Hertel CC. Simple and rapid high-performance liquid chromatographic assay for zidovudine (azidothymidine) in plasma and urine. Journal of Chromatography 1988; 430: 420-423.
21. Veldkamp AI, Sparidans RW, Hoetelmans RMW and Beijnen JH. Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed phase high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B 1999; 736: 123-128.
22. Weller S, Radomsky KM, Lou Y and Stein DS. Population pharmacokinetics and pharmacodynamic modelling of abacavir (1592U89) from a dose-ranging, double-blind, randomised monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrobial Agents and Chemotherapy 2000; 44: 2052-2060.
23. Wientjes MG and Au J. High-performance liquid chromatographic analysis of 2′,3′-dideoxyinosine in biological samples. Journal of Chromatography 1991; 563: 407-413.